PRME News and Press, First Trust Heitman Global Prime Real Estate ETF From 03/06/24

2024-03-06 16:16:26 ET More on Metagenomi, Inc. Stocks To Watch: Eyes On Broadcom, Target, Costco, Rivian And Small Caps Metagenomi Begins Genetic Treatment IPO Rollout Moderna-backed Metagenomi sees stock fall 31% after $94M IPO Metagenomi prices initial off...

-- Maturing into clinical-stage company; on-track to file IND application or CTA for PM359 in 1H 2024, with initial data expected in 2025 -- -- Progressing broader portfolio across core areas of focus; expect to initiate IND-enabling activities in first liver and ocular disease progra...

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in two upcoming conferences: ...

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten upsized public offering of 22,560,001 shares ...

2024-02-15 04:39:41 ET More on Prime Medicine Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing Prime Medicine stock falls on proposed public offering of common stock Prime Medicine wins up to $15M to find cure for cystic fibrosis ...

CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten upsized public offering of 19,200,001 shares o...

2024-02-14 16:16:40 ET More on Prime Medicine Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing Prime Medicine wins up to $15M to find cure for cystic fibrosis Stifel cuts Prime Medicine to hold, cites quieter catalyst outlook ...

CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an underwritten public offering of $125.0 million of sh...

2024-02-12 01:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime...